Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Trial Profile

Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Registrational; Therapeutic Use
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 14 Jul 2016 Pooled results (n=3736) of two phase III trial (NCT01373281, NCT01374516) published in the Journal of Infectious Diseases
    • 13 Oct 2015 Results of this and other two trials (see profile 41674 and 200833) published in the Vaccine
    • 28 Apr 2014 Primary endpoint 'significant superiority of dengue vaccine vs placebo in disease occurrence rate' has been met, according to a Sanofi Pasteur media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top